Atacand

2020: AstraZeneca sold the rights on Atakand of Cheplapharm Arzneimittel company

At the end of October, 2020 AstraZeneca sold the commercial rights to the two medicines of the German pharmaceutical company Cheplapharm Arzneimittel. Business on production of the cardiovascular medicines "Atakand" and "Atakand Plus" was given for $400 million.

According to AstraZeneca, the transaction which end is expected in the fourth quarter 2020 will not influence its financial forecast. At the same time $250 million from $400 million will be paid upon completion of the transaction, and the rest - in the first half of 2021. AstraZeneca will continue to make and deliver the medicines "Atakand" and "Atakand Plus" to medical institutions and drugstores within three more years - such is duration of the transient period stipulated in the agreement.

AstraZeneca sold business on production of cardiovascular medicines for $400 million

AstraZeneca also signed the supplementary agreement with Cheplapharm company. This company since 2018 owns the rights to distribution Atakand and Atakand Plus in Europe, and now will be able to sell this medicine approximately in 70 countries. Atakand (active ingredient a blocker of receptors of angiotensin, kandesartan) is the medicine which is released according to the recipe and approved for treatment of heart failure and arterial hypertension. It was developed in 1990 and is available in the market since 1997. Atakand Plus is used only for treatment of arterial hypertension.

The company AstraZeneca intends to focus on production of new drugs in new spheres of therapy, in particular on antineoplastic medicines. It is considered that the London company is ahead of the competitors in a race on production of the most effective remedies for cancer therapy. Sales of these drugs, including popular medicine for cancer therapy of easy Imfinzi, already played a key role in development of the company.^[1]

Notes